Prediabetes in Patients Treated With Antipsychotic Drugs
Authors:
- Peter ManuPMPeter Manu
- Christoph U. CorrellCCChristoph U. Correll
- Ruud van WinkelRWRuud van Winkel
- Martien WampersMWMartien Wampers
- Marc De HertMHMarc De Hert
- 27 December 2011
- journal article
- research article
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 73 (04) , 460-466
Abstract
In 2010, the American Diabetes Association (ADA) proposed that individuals with fasting glucose level of 100-125 mg/dL (5.6-6.9 mmol/L) or glucose level of 140-199 mg/dL (7.8-11.0 mmol/L) 2 hours after a 75-g oral glucose tolerance test or hemoglobin A(1c) 5.7%-6.4% be classified as prediabetic, indicating increased risk for the emergence of diabetes mellitus. At the same time, the ADA formulated guidelines for the use of metformin for the treatment of prediabetes. To determine the prevalence of prediabetes in a cohort of psychiatrically ill adults receiving antipsychotics and to compare the clinical and metabolic features of prediabetic patients with those of patients with normal glucose tolerance and those with diabetes mellitus. The 2010 ADA criteria were applied to a large, consecutive, single-site European cohort of 783 adult psychiatric inpatients (mean age: 37.6 years) without a history of diabetes who were receiving antipsychotics. All patients in this cross-sectional study underwent measurement of body mass index (BMI), waist circumference, oral glucose tolerance test, and fasting insulin and lipids from November 2003 through July 2007. 413 patients (52.8%) had normal glucose tolerance, 290 (37.0%) had prediabetes, and 80 (10.2%) had diabetes mellitus. The fasting glucose and/or hemoglobin A(1c) criteria were met by 89.7% of prediabetic patients. A statistically significant intergroup gradient from normal glucose tolerance to prediabetes and from prediabetes to diabetes mellitus was observed for waist circumference, triglycerides, fasting insulin levels, and frequency of metabolic syndrome (P = .02 to P < .0001). Only 19/290 prediabetic patients (6.6%) met the 2010 ADA criteria for treatment with metformin. Prediabetes is highly prevalent in adults treated with antipsychotic drugs and correlates with markers of increased intraabdominal adiposity, enhanced lipolysis, and insulin resistance. Criteria for using metformin to prevent the emergence of diabetes mellitus may need to be revised for this population.Keywords
This publication has 23 references indexed in Scilit:
- Antipsychotic drugs and obesityTrends in Molecular Medicine, 2011
- The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohortDiabetes Research and Clinical Practice, 2010
- Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)Journal of Affective Disorders, 2010
- Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia PatientsNeuropsychopharmacology, 2010
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-AnalysisNeuropsychopharmacology, 2010
- The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic studyPharmacoepidemiology and Drug Safety, 2009
- Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs populationInternational Clinical Psychopharmacology, 2009
- Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second‐generation antipsychoticsBipolar Disorders, 2008
- Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophrenia Research, 2007
- To What Extent Do the PANSS and CGI-S Overlap?Journal of Clinical Psychopharmacology, 2006